Physicochemical Properties
| CAS # | 2252278-57-0 |
| PubChem CID | 164517210 |
| Appearance | Typically exists as solid at room temperature |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Heavy Atom Count | 58 |
| Complexity | 1760 |
| Defined Atom Stereocenter Count | 8 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Apoptosis inducer 7 (Compound 5I) has the strongest anticancer effect on human cancer cell lines (0.098–50 μM, 96 hours) [1]. Compound 5I, also known as Apoptosis Inducer 7, is known to cause HCT-116 cells to undergo apoptosis. This induction is linked to the overexpression of the pro-apoptotic protein Noxa and the downregulation of the anti-apoptotic protein c-Flip [1]. |
| ln Vivo | Tumor development is inhibited by Apoptosis Inducer 7 (Compound 5I) (5 mg/kg; i.p.; 3 times per week for 14 days; LL/2 xenograft model in C57/BL6J mice) [1]. |
| Cell Assay |
Cytotoxicity assay [1] Cell Types: human breast cancer MDA-MB-231 cells, human lung cancer A549 cells, human colorectal cancer HCT-116 cells, human liver cancer HepG-2 cells and a non-tumor human breast epithelial cell MCF- 10A battery. Tested Concentrations: 0.098-50 μM Incubation Duration: 96 hrs (hours) Experimental Results: MDA-MB-231, A549, HCT-116, HepG-2 and MCF-10A were inhibited with IC50 values of 0.22, 0.15, 0.42, 0.14 and 1.03 μM respectively. Cell cycle analysis [1] Cell Types: HCT-116 Cell Tested Concentrations: 0.5, 0.75 and 1.0 μM Incubation Duration: 24 hrs (hours) Experimental Results: More than 40% of the cells were detected to be in sub-G1 phase. Western Blot Analysis[1] Cell Types: HCT-116 Cell Tested Concentrations: 0.5, 0.75 and 1.0 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induction of PARP, caspase cleavage and reduction of c-Flip and HDAC3 protein levels. |
| Animal Protocol |
Animal/Disease Models: KARPAS-422 mouse subcutaneousxenograft [1] Doses: 5 mg/kg Route of Administration: intraperitoneal (ip) injection; 3 times a week for 14 days. Experimental Results: Tumor growth was inhibited, the inhibition rate was 62.3%, and there was no significant weight loss. |
| References |
[1]. Synthesis and antitumor effects of novel 18β-glycyrrhetinic acid derivatives featuring an exocyclic α,β-unsaturated carbonyl moiety in ring A. Bioorg Chem. 2020 Oct;103:104187. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |